ARS Pharmaceuticals Q2 neffy revenue rises as epinephrine market share doubles

ARS Pharmaceuticals

13/08/2026 21:13

Overview
US biopharma firm's Q2 neffy net product revenue rose, U.S. epinephrine market share doubled yr/yr
Company posted Q2 net loss of $62.3 mln, with higher operating expenses from media and sales expansion
Operating expenses to be reduced in 2H 2026 as focus shifts to targeted provider engagement

Outlook
Company expects 2H 2026 SG&A and R&D expenses of $114 mln to $126 mln
Company anticipates path to cash flow breakeven by end of 2027
Interim Phase 2b data for CSU program expected in Q1 2027

Result Drivers
TARGETED PROVIDER ENGAGEMENT - Co said shift from broad consumer marketing to targeted high-volume prescriber engagement supported neffy market share growth
SALES FORCE EXPANSION - Co completed expansion of field sales organization, focusing efforts on highest-value prescribers
INCREASED PRESCRIBER BASE - Over 16,000 unique prescribers in Q2, nearly threefold increase yr/yr

Company press release: ID:nGNX341s4d

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Loss Per Share
 
$0.63
 
Q2 Net Loss
 
$62.34 mln
 
Q2 Operating Expenses
 
$95.12 mln
 
Q2 Operating Income
 
-$61.47 mln
 

Analyst Coverage
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy."
Wall Street's median 12-month price target for ARS Pharmaceuticals Inc is $31.00, about 412.4% above its August 12 closing price of $6.05

Reuters Recommended Reads
Aug 12 - Omeros Q2 YARTEMLEA net revenue jumps 190%
Aug 11 - Aquestive Therapeutics Q2 revenue beats on Suboxone strength
Aug 12 - Liquidia Q2 revenue jumps on YUTREPIA sales

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)